• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy.

作者信息

He Sike, Liu Haoyang, Chen Junru, Zeng Hao

机构信息

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

出版信息

J Transl Med. 2024 Mar 3;22(1):232. doi: 10.1186/s12967-024-05014-z.

DOI:10.1186/s12967-024-05014-z
PMID:38433208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910860/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a0/10910860/a5699c83194b/12967_2024_5014_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a0/10910860/a5699c83194b/12967_2024_5014_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a0/10910860/a5699c83194b/12967_2024_5014_Fig1_HTML.jpg

相似文献

1
Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy.在接受二线或三线酪氨酸激酶抑制剂-免疫检查点抑制剂联合治疗的转移性透明细胞肾细胞癌患者中验证Meet-URO评分
J Transl Med. 2024 Mar 3;22(1):232. doi: 10.1186/s12967-024-05014-z.
2
Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. upfront 细胞减灭性肾切除术治疗转移性肾细胞癌患者的结局获益：TriNetX 数据库分析。
PLoS One. 2024 Mar 28;19(3):e0299102. doi: 10.1371/journal.pone.0299102. eCollection 2024.
3
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.一线免疫治疗联合治疗后转移性透明细胞肾细胞癌二线治疗的无进展生存期。
Eur Urol. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017. Epub 2022 Nov 4.
4
Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study.酪氨酸激酶抑制剂与免疫检查点抑制剂联合治疗转移性肾细胞癌的疗效——一项回顾性研究
J Oncol Pharm Pract. 2020 Apr;26(3):556-563. doi: 10.1177/1078155219854797. Epub 2019 Jun 19.
5
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.一线双重免疫检查点抑制剂治疗与包含免疫检查点抑制剂和酪氨酸激酶抑制剂的联合治疗方案用于晚期肾细胞癌：使用真实世界数据的有效性比较分析。
Int J Clin Oncol. 2024 Apr;29(4):473-480. doi: 10.1007/s10147-024-02471-w. Epub 2024 Feb 12.
6
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).程序性死亡受体 1（PD-1）或程序性死亡配体 1（PD-L1）抑制剂（IO）治疗后转移性肾细胞癌（mRCC）进展的临床结局：Meet-URO 集团真实世界研究（Meet-Uro 7）。
Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791.
7
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.一线免疫检查点抑制剂联合酪氨酸激酶抑制剂在转移性肾细胞癌中根据 IMDC 风险组的比较效果：一项荟萃分析。
Immunotherapy. 2021 Jun;13(9):783-793. doi: 10.2217/imt-2021-0005. Epub 2021 Apr 28.
8
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.将免疫检查点抑制联合酪氨酸激酶抑制作为转移性肾细胞癌的一线和后续治疗。
Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18.
9
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.仑伐替尼联合或不联合依维莫司治疗免疫检查点抑制剂和血管内皮生长因子受体酪氨酸激酶抑制剂治疗后转移性肾细胞癌患者。
Oncologist. 2021 Jun;26(6):476-482. doi: 10.1002/onco.13770. Epub 2021 Apr 21.
10
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.一线免疫检查点抑制剂联合治疗时代的治疗序贯策略，转移性透明细胞肾细胞癌患者面临的新挑战。
Bull Cancer. 2022 May;109(2S):2S31-2S38. doi: 10.1016/S0007-4551(22)00236-3.

本文引用的文献

1
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.预处理转移性肾细胞癌接受免疫治疗中先前肾切除术的预后价值：Meet-URO 15 研究的亚分析。
J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.
2
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.Meet-URO评分在接受二线和三线卡博替尼治疗的转移性肾细胞癌患者中的应用。
Ther Adv Med Oncol. 2022 Feb 26;14:17588359221079580. doi: 10.1177/17588359221079580. eCollection 2022.
3
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
《肾癌临床实践指南》第 3 版 2022 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001.
4
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).接受纳武单抗治疗的转移性肾细胞癌患者的炎症指标和临床因素：一种新型预后评分系统的开发（Meet-URO 15研究）
Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 2021.
5
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.